The FDA on December 12, 2025, approved AKEEGA® with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic Castration-Sensitive Prostate Cancer (mCSPC), as determined by an FDA-approved test. AKEEGA® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
